Synexus celebrates opening of two new Dedicated Research Centres in Pretoria

09 Sep 2009
UK-based Synexus, the world's largest multi-national company dedicated to the recruitment and running of clinical trials, celebrated the first phase of its South African expansion programme today.
At the formal opening of Synexus' two new Dedicated Research Centres, Dr Abul Rahman, Chief of Operations, Gauteng Health Office, MEC Health, declared the Stanza Bopape centre in Mamelodi open, whilst Dr Ian Smith, founder of Synexus, performed the honours at the Watermeyer centre in Meyerspark. They were joined by members of the local community and business representatives, including Michael Fort, Synexus Chief Executive, to celebrate this important occasion and to reiterate the company's long term plans to continue developing business in this region where pharmaceutical and biotech companies are continuing to demand an increased number of clinical trials.

In October 2008 Synexus announced its intention to double its clinical trial capacity in South Africa and Michael Fort acknowledged that this event signalled their on-going commitment to that goal: "We are on track to meet our aim of doubling clinical trials capacity here, and expect to do so before the end of 2009. The facilities at our new centres are excellent, as are the medical staff working for us here. We have a great team on board to lead our developments in South Africa, with Dr Sanet Aspinall and Dr Luthando Adams bringing tremendous local and professional experience to add to our strengths. We hope to be celebrating the opening of our next centre in Soshanguve within the coming months."

The new centres are in addition to Synexus' existing South African research centre which has a 36 bed phase I and IIa clinical trials unit with a well established record for delivering high quality trials on time. All the centres will benefit from the use of new, state of the art equipment including a DXA scanner and digital x-ray facilities.

Dr Ian Smith, founder of Synexus, is confident of the long term prospects for Synexus operations in South Africa: "From the start of our operations here we have seen impressive year-on-year growth. The combination of the large patient population and the highly skilled medical community make it a sought after destination for pharmaceutical and biotech companies who are finding patient recruitment increasingly difficult. We currently have four major trials underway here, all part of wider international studies, as well as more than thirty Phase I to Phase III trials."

Dr Sanet Aspinall, who leads Synexus' operations in South Africa explained how working in partnership with the local community has helped deliver the state-of-the-art Stanza Bopape centre: "Synexus signed a Memorandum of Understanding with the Stanza Bopape Community Trust to construct a facility on its premises. The Trust is a non-profit making organisation providing a range of services including healthcare to improve quality of life for the local community. We now have the first custom-built medical research centre to be constructed in a township in South Africa and are looking forward to working together with our community partners."

Back to top ^

Feasibility

If you would like an assessment on a clinical trial please send us your details and we will get back to you.

Contact Us

Have more questions? Contact us for more information

Contact Us

Synexus Limited, Registered in England and Wales, Registered number 3724238, Registered Office: Sandringham House, Ackhurst Park, Chorley , Lancashire, PR7 1NY